TBPH Q4 2017 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-20.7% YoY

Gross Profit

$1M31.0% margin

Operating Income

-$79M-1753.6% margin

Net Income

-$87M-1925.2% margin

EPS (Diluted)

$-1.64

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$441M

Total Liabilities

$326M

Stockholders' Equity

$115M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$6M	-20.7%
Gross Profit	$1M	$5M	-69.2%
Operating Income	-$79M	-$58M	-36.9%
Net Income	-$87M	-$67M	-29.1%